A carregar...
Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
Risankizumab has demonstrated efficacy in phase III trials in patients with moderate‐to‐severe plaque psoriasis. The exposure–response relationships for risankizumab efficacy (Psoriasis Area and Severity Index (PASI)75, PASI90, PASI100, and static Physician's Global Assessment (sPGA)0/1) at wee...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7006881/ https://ncbi.nlm.nih.gov/pubmed/31355921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1594 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|